Sell RIM!: Against ...
Health Care: Drugs
ARCA biopharma Inc. (ABIO: NASDAQ)
$0.48 -0.02 | -3.81%
06/04/12 - 01:42 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 0.00 | 0.00 | 0.00 | 15.25M |
| Cost of Sales | -602.00K | -338.00K | -457.00K | -2.28M |
| Gross Operating Profit | 602.00K | 338.00K | 457.00K | 17.54M |
| Selling, General, and Administrative Expenses | 5.05M | 6.07M | 12.84M | 14.94M |
| Research & Development | 2.32M | 3.11M | 10.01M | 27.76M |
| Operating Income before D & A (EBITDA) | -6.76M | -8.84M | -22.39M | -25.17M |
| Depreciation & Amortization | 602.00K | 338.00K | 457.00K | 2.28M |
| Interest Income | 2.00K | 763.00K | 217.00K | 2.43M |
| Other Income - Net | 2.00M | 0.00 | 25.28M | 2.24M |
| Special Income / Charges | 0.00 | 0.00 | -6.00M | -4.67M |
| Total Income Before Interest Expenses (EBIT) | -5.36M | -8.41M | -11.23M | -29.92M |
| Interest Expense | 5.00K | 8.00K | 185.00K | 0.00 |
| Pre-Tax Income | -5.36M | -8.42M | -11.42M | -29.92M |
| Income Taxes | 0.00 | 0.00 | -2.28M | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -5.36M | -8.42M | -9.14M | -29.92M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -5.36M | -8.42M | -9.14M | -29.92M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -5.36M | -8.42M | -9.14M | -29.92M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-5.36M | -8.42M | 4.74M | -22.78M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -5.36M | -8.42M | -10.05M | -29.92M |
| Basic EPS from Continuing Ops. | -0.53 | -0.99 | -1.42 | -11.17 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.53 | -0.99 | -1.42 | -11.17 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.53 | -0.99 | -1.42 | -11.17 |
| Basic Normalized Net Income/Share | -0.53 | -0.99 | 0.74 | -8.50 |
| EPS fr Continuing Ops. | -0.53 | -0.99 | -1.42 | -11.17 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.53 | -0.99 | -1.42 | -11.17 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.53 | -0.99 | -1.42 | -11.17 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.53 | -0.99 | 0.74 | -8.50 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ABIO
- Portfolio NameUser Type
- Userbuddy62370 Portfolio 1
- UserKumaran
- UserSUPRATRADE NEW-BUY LIST-240...
Latest ABIO Headlines from TheStreet
- InfoLogix, Netlist: Midday Volume Plays 05.17.10 | 01:05 pm
- Arca BioPharma Patent Deja Vu: BioBuzz 03.29.10 | 06:03 am
- Sirius XM, ARCA biopharma: Early Volume Plays 03.26.10 | 09:03 am
- Brazilian Telecom, Agria: Midday Volume Plays 11.24.09 | 01:11 pm
- ARCA, FortuNet: Midday Volume Plays 11.23.09 | 01:11 pm
- Funds Sell $4M Worth of Pain Therapeutics 06.11.09 | 09:06 am
- Ford, Deere, Cisco Systems Are Big Movers 06.01.09 | 05:06 pm
- FDA Wants ARCA To Run More Tests On Heart Drug 06.01.09 | 11:06 am
- The Second Dendreon Wave
05.18.09 | 02:05 pm
Press Releases for ABIO
- GencaroTM's Norepinephrine Lowering Likely Contributes To Its Effect In Atrial Fibrillation Prevention - Business Wire 03.26.12 | 12:03 pm
- GencaroTM Atrial Fibrillation Data Selected For Presentation At American College Of Cardiology 61st Annual Scientific Session & Expo - Business Wire 03.20.12 | 08:03 am
- ARCA Biopharma Announces Additional Patent Issued For Methods For Treatment With Bucindolol Based On Genotype Of Patient - Business Wire 01.19.12 | 08:01 am
- CEO Of ARCA Biopharma To Speak On Use Of Biomarkers And Implications Of Personalized Medicine At New Paradigms Conference On January 12, 2012 - Business Wire 01.05.12 | 08:01 am
- Dr. Michael Bristow, CEO, ARCA Biopharma (Photo: Business Wire) - Business Wire 12.30.11 | 08:12 am
- ARCA Biopharma Announces Private Placement Of $1.75 Million With Institutional Investors - Business Wire 12.22.11 | 08:12 am
- Kaplan Meier Curves By Beta-1 389 Arg/Gly Polymorphism. (Graphic: Business Wire) - Business Wire 11.16.11 | 11:11 am
- Dr. Michael Bristow, CEO, ARCA Biopharma (Photo: Business Wire) - Business Wire 11.11.11 | 08:11 am
- Two GencaroTM Atrial Fibrillation Abstracts Accepted For Presentation At The American Heart Association Scientific Sessions 2011 - Business Wire 08.10.11 | 08:08 am
- ARCA Biopharma Announces Planned Expansion Of Gencaro Development To Atrial Fibrillation - Business Wire 05.26.11 | 08:05 am
Partner Headlines for ABIO
- Will the Next Apple or Google Be Found Among These Micro Caps? - Seeking Alpha 08.18.11 | 09:08 am
- Top Percentage Gainers and Losers as of 2pm 05/13/11 (ABIO, GFRE, DDS, APL, DF, VRML, DAR, SWSH, ONTY, GS, RMBS, LPHI, GGS, CA, NVDA, IMRS, MNTX, MPG, GTY) - Benzinga 05.13.11 | 02:05 pm
- Morning Market Movers (ABIO, LBIX, CGNX, AEIS) - Benzinga 05.03.11 | 09:05 am
- UPDATE 1-Arca reaches agreement with FDA on heart-drug study - Reuters 05.17.10 | 09:05 am
- UPDATE 1-ARCA gets U.S. patent related to heart drug; shrs soar - Reuters 03.26.10 | 10:03 am
